• Insured
  • Counsel-reviewed
  • De-identified
Call +1 656 800 9088Partner portal
Call+1 656 800 9088Partner portal

Can a pharmaceutical company license its data to AI companies?

Parts of it, and with a long list of exclusions. A drug company’s most valuable data, compounds, trial results and patient records, is protected by patents, trade secrets and privacy law, and is not what is described here. What can sometimes be considered is the operations record around the science: procedures, quality systems and how teams coordinate.

What's my data worth?

What a pharmaceutical company has that is licensable

Standard operating proceduresWritten methods for production steps, cleaning, calibration and record keeping, with their revision histories.
Quality deviation and corrective action recordsWhat went wrong in a process, how it was investigated and what was changed, with product and person details removed.
Project coordination recordsPlanning documents and team chat about timelines, supplier problems and handoffs between groups.
Training materialsHow staff are taught a method, including assessments and the common mistakes covered.
Technical support exchangesQuestions between sites about equipment and methods, and the answers.

Where the confidential science sits

Compound structures, formulations, assay results and regulatory filings are trade secrets or are covered by patents, and companies guard them closely. The approach starts by excluding anything that describes a product under development, and then looks at what remains.

Quality systems are unusually well documented

Regulated production requires written procedures, controlled revisions and documented investigations of every deviation. That discipline produces records with a clear structure and a stated reason for each change, which is not common in other industries.

Patients and trial participants are protected

Records about people in trials or treatment, including adverse event reports, carry consent terms and strict privacy rules. They are out of scope. Where a document mentions such a person, the whole document is reviewed or dropped.

What stays out for a pharmaceutical company

Trial and patient dataParticipant records, adverse event reports and clinical results stay out of every set.
Formulations and compound dataAnything that describes what a product is made of, or how its active ingredient works, stays out.
Regulatory filings and correspondenceSubmissions and agency exchanges are confidential and are screened with counsel.
Supplier and partner termsContract manufacturers and research partners usually have confidentiality terms that block sharing.

An example, invented for illustration

A specialty drug manufacturer with 200 employees and a long-running plant selects its cleaning and calibration procedures, its quality deviation write-ups and its training materials for new operators. The quality head removes anything naming a product under development, counsel checks the partner agreements, and the cleaning step replaces staff names and batch numbers. The owner and the quality head approve a sample that shows a deviation from first report to the corrective action.

Questions owners ask about this

Can drug discovery data be licensed?

That is a different and much more sensitive matter, with patents and trade secrets at stake, and it is outside this page. This describes only the operations records around the science.

Are our SOPs confidential?

Often, and many are controlled documents. Leadership decides which can be shared in a de-identified form, and the quality head approves the sample.

Does a contract manufacturer’s data count as ours?

Usually not. Records produced for a client under a production agreement tend to belong to the client, and are left out unless they agree.

Is a small biotech a candidate?

Possibly, if it has consistent operations records over several years. A company with only research notes and no procedures has less to offer in this form.

Didn't find your question? Ask us directly.

Keep reading

Records to look at first